P52 The Dermatology Life Quality Index in 70 guidelines and 38 registries: a systematic review involving 55 countries: the International Standard of Care in Dermatology

Clicks: 3
ID: 318361
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #270 of 313 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and aims The Dermatology Life Quality Index (DLQI) is the most widely used instrument to measure the impact of skin conditions on patients’ quality of life (QoL) in routine practice and to inform clinical decision making. This study aimed to systematically review publications using DLQI data from dermatology registries and from its use in dermatology guidelines. Methods A systematic search of MEDLINE, Embase and Scopus identified articles describing registries collecting routine clinical data and guidelines incorporating the DLQI in clinical decision making. Additionally, national and regional dermatology organizations were surveyed to determine the use of the DLQI in guidelines and registries, and websites of English language organizations that included dermatological guidelines were screened. Results Of 2593 publications identified, 195 met inclusion criteria. Overall, 56 studies from 55 different countries referenced both ‘DLQI’ and ‘dermatological guidelines’, while 123 studies used DLQI data from 59 registries. Twenty were generic publications referring to guidelines or registries and the DLQI, and two were guideline adaptations. Over half of studies using guidelines (29/55, 53%) focused on psoriasis, 21% atopic dermatitis/eczema, 12% hidradenitis suppurativa, 11% urticaria, 7% alopecia, 4% rosacea and 4% acne, and 2% each for bullous disease, cellulitis, actinic keratosis, vitiligo and psoriasis with psoriatic arthritis. Studies used data from 37 different registries where diseases studied were psoriasis (73/120 studies, 59.3%), atopic dermatitis (15.8%), psoriasis and psoriatic arthritis (9.2%), eczema (5.0%), psoriatic arthritis (3.3%), hidradenitis suppurativa (1.7%) and urticaria (1.7%) and 1 study each (0.8%) with alopecia, lupus erythematosus, palmoplantar pustulosis and pemphigus. Overall, 59 registries were authored by dermatology groups, e.g. British Association of Dermatologists Biologic Interventions Register, 29 by governments, 9 by pharmaceutical companies,10 by trusts/foundations and 2 by societies. Conclusions There is accumulating evidence of the application of the DLQI in registries and clinical and reimbursement guidelines. The uniform use of DLQI in multiple registries internationally contributes to improved global health and facilitates meaningful comparison of QoL data.
Reference Key
openalex_W7165628660 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Annabelle Xiao Hui Lim, Jeffrey Johns, Jui Vyas, Faraz M Ali, John R Ingram, Muaad Eghlileb, Alison K Y Chao, Sam Salek, A.Y. Finlay
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag151.090
URL
https://doi.org/10.1093/bjd/ljag151.090
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.